CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Be Biopharma
Company type: Therapeutics
Main focus: B cell engineering
Company stage: Pre-clinical
Diseases: Cancer
Genome-editing tool: CRISPR
Funding stage: Series B
Location: Cambridge, MA, USA
Website: https://www.be.bio
Pipeline: Not disclosed
Partners:
Be Biopharma is a pre-clinical-stage company focused on the engineering of B cells via CRISPR, to produce engineered B Cell medicines (BeCMs). Once differentiated in plasma cells ex vivo, BeCMs can be infused into patients and act as cell factories to produce the required therapeutic molecules.
